TrioxBio Inc. is a clinical-stage biotech company specializing in the development of compounds to treat diseases and medical conditions related to the pathological overproduction of Nitric Oxide (NO).
Over 100 white papers and articles have been published documenting how the overproduction of nitric oxide is linked to harmful effects on the human body and strongly believed to be responsible for numerous medical conditions, such as intradialytic hypotension and vasoplegic syndrome (two examples of severe hypotension), migraine and cluster headache.
TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a Nitric Oxide Synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity.
TrioxBio's leading candidate, MTR-107, indicated for the prevention of recurrent intradialytic hypotension, an unmet medical need, received orphan drug designation from the FDA in August 2016. In addition, its development program received Fast Track designation from this agency in May 2018. MTR-107 phase IIb clinical study activities planned for Q4 of 2018.
Our mission is our commitment to improving quality of life. By way of our existing products and pending approvals across our various markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.